New drug A3907 tested for rare liver disease PSC
Disease control
Terminated
This study tested a drug called A3907 in 18 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The main goal was to see if the drug is safe and tolerable. The study was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 13, 2026 16:03 UTC